Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

NEOVAXSYN INC

UEI: EHMTBALCKFE8CAGE: 7RK00

NEOVAXSYN INC is a federal contractor, registered under UEI EHMTBALCKFE8 and CAGE code 7RK00. It has been awarded $4,551,873 in federal contracts. Primary work spans Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) and Unknown NAICS. Top awarding agencies include Department Of Health And Human Services.

Contact Information

Registration and classification details

Registration

UEI Code

EHMTBALCKFE8

CAGE Code

7RK00

Entity Structure

Corporate Entity (Not Tax Exempt)

Established

N/A

Business Classifications

For Profit OrganizationAsian-Pacific American OwnedMinority-Owned Business

NAICS Codes

541714Research and Development in Biotechnology (except Nanobiotechnology)(Primary)

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

AI Capability Profile

NEOVAXSYN INC specializes in the design and development of next-generation immunopreventive platforms targeting complex viral pathogens, with a focused expertise in nanovaccine engineering and broadly neutralizing antibody (bnAb) induction against HIV-1. The company leverages advanced antigen design...

NEOVAXSYN INC specializes in the design and development of next-generation immunopreventive platforms targeting complex viral pathogens, with a focused expertise in nanovaccine engineering and broadly neutralizing antibody (bnAb) induction against HIV-1. The company leverages advanced antigen design, nanoparticle delivery systems, and structural immunology to engineer precision immunogens capable of eliciting durable, cross-reactive humoral responses. Their technical proficiency spans rational vaccine design, epitope mapping, and immunogen optimization for difficult-to-target conserved regions of viral envelopes, positioning them at the forefront of HIV vaccine innovation. Key differentiators include their ability to translate computational immunology insights into clinically viable nanoscale formulations and their iterative, data-driven approach to overcoming immune evasion mechanisms inherent in HIV. The contractor maintains a consistent and deep engagement with the Department of Health and Human Services, delivering high-impact research and development solutions primarily through SBIR and direct R&D contracts. Their work for HHS centers on translational vaccine development, bridging early-stage discovery with preclinical validation, and aligning closely with NIH and CDC priorities in infectious disease prevention. NEOVAXSYN INC’s primary industry focus is in Research and Development in the Physical, Engineering, and Life Sciences (NAICS 541715), where they operate as a niche biotech innovator specializing in infectious disease immunology and nanomedicine. Their market positioning is defined by cutting-edge vaccine platforms that address persistent global health challenges, particularly those requiring novel immune activation strategies beyond conventional approaches. As a small business structured as a 2L entity based in Ames, Iowa, NEOVAXSYN INC operates with agility and scientific rigor, focusing exclusively on federally funded R&D initiatives. While currently holding no formal government certifications, their consistent award history with HHS underscores their credibility and technical competence within the federal biomedical research ecosystem.

Key Performance Metrics

Awards Count

8

All time

Active

2

Currently performing

Completed

6

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency
Awards by NAICS
Awards by Agency Over Time
Awards by Place of Performance

Compete with NEOVAXSYN INC

Track the contractors you bid against, and the work they win

Award history, agency mix, and NAICS coverage for NEOVAXSYN INC

AI-powered matching against your own capabilities and past performance

Teaming and subcontracting signals on every award

Automated alerts when a competitor wins in your market

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS

Open opportunities in NEOVAXSYN INC's top NAICS codes and agencies

NAICS: 541715
New
Federal
U.S. Army Contracting Command – Watervliet Arsenal (ACC-WVA) Organic Industrial Base (OIB) Modernization Commercial Solutions Opening (CSO)
Solicitation # W911PT26SC001
The U.S. Army Contracting Command – Watervliet Arsenal (ACC-WVA) has issued solicitation W911PT26SC001, a Commercial Solutions Opening (CSO) authorized under the National Defense Authorization Act for Fiscal Year 2026 and DFARS Subpart 212.70. This competitive solicitation is open until September 30, 2027, and is designed to acquire innovative commercial products, technologies, and services to modernize the Army's Organic Industrial Base. The scope focuses on integrating manufacturing resources, linking legacy analogue systems with digital systems, and expanding modeling and simulation to enhance the delivery of materiel solutions. The CSO targets both traditional and non-traditional business entities, including small businesses and foreign-owned firms, provided they maintain an active System for Award Management (SAM) profile and a Unique Entity ID. The acquisition process follows a multi-phased approach consisting of a written solution brief, an optional presentation or pitch, and a final Request for Commercial Solution Proposal (CSP). Evaluation is based on responsiveness, technical merit, uniqueness, and price reasonableness. Successful responses may result in fixed-price contracts awarded under FAR Part 12 Commercial Item Procedures. Current Areas of Interest (AoIs) include advanced cannon technology, electrical infrastructure improvements at Building 120, chromium facility conversion, automated manufacturing for minor components, automated cooling tower treatments, advanced CNC vertical turning lathes, and advanced tooling for radial forging. Performance is primarily located at Watervliet Arsenal and Benet Laboratories, with a general period of performance not to exceed 12 months unless otherwise specified.
W6QK Acc Wva

POSTED

about 17 hours ago

DEADLINE

in 11 months
View Details
NAICS: 541715
New
Grant
Coordinating Center for National Resource Network for the Study of Human Auditory and Vestibular Disorders (U24 Clinical Trial Not Allowed)
Solicitation # RFA-DC-28-002
Solicitation RFA-DC-28-002 is a Notice of Funding Opportunity from the National Institutes of Health, specifically the National Institute on Deafness and Other Communication Disorders, to establish a Coordinating Center for the NIDCD National Human Ear Resource Network. This collaborative network provides human inner and middle ear tissues to researchers for basic and clinical studies aimed at advancing the treatment of auditory and vestibular disorders. The Coordinating Center is responsible for maintaining network cohesiveness through the planning of workshops, symposia, and regular meetings, providing updates to laboratories, and managing communication with the public and scientific community regarding tissue donation. The maximum project period is five years, with a budget limit of 200,000 dollars in direct costs per year. Applicants, including for-profit organizations and small businesses, must maintain active registrations in SAM, eRA Commons, and Grants.gov. Proposals are evaluated based on the significance of the proposed center and the qualifications of the investigators, with additional reviews for human subject protections, inclusion policies, and the use of vertebrate animals. Key requirements include a structured Data Management and Sharing Plan and adherence to cybersecurity guidelines, including a 48-hour incident reporting window. The application process is entirely electronic and requires several standard PHS and SF424 forms, with a response deadline of March 5, 2027.
National Institutes Of Health

POSTED

1 day ago

DEADLINE

in 5 months
View Details
NAICS: 541715
New
Grant
National Resource Network for the Study of Human Auditory and Vestibular Disorders (U24 Clinical Trial Not Allowed)
Solicitation # RFA-DC-28-001
Solicitation RFA-DC-28-001 is a Notice of Funding Opportunity issued by the National Institutes of Health under the Department of Health and Human Services to support the NIDCD National Human Ear Resource Network. The objective is to maintain a collaborative network of laboratories that serve as a national technological resource, providing human inner and middle ear tissues to researchers for basic and clinical studies to advance the treatment of auditory and vestibular disorders. The scope of work includes processing human temporal bones from the National Hearing and Balance Organ Donor Program, uploading images and medical data to EarBase, sharing gene-expression data via the gEAR repository, and providing technical instruction to increase the number of skilled researchers in the field. The NIDCD intends to commit 3.6 million dollars in FY 2028 to fund up to six awards, with a maximum project period of five years. Individual awards are limited to 450,000 dollars in direct costs per year, with an additional 150,000 dollars available for specific subawards. Applications are due on March 05, 2027, and November 01, 2027, with staggered start dates ranging from July 2027 to July 2028. Evaluation is based on the experience of the investigators, the adequacy of the institutional environment, and the protection of human subjects. Applicants must maintain active SAM registration and a Unique Entity Identifier, and they must provide a Data Management and Sharing Plan and a Material Transfer Agreement. Compliance with the Cybersecurity Act of 2015 is required, including the development of an incident response plan and notification of cybersecurity incidents within 48 hours of discovery.
National Institutes Of Health

POSTED

1 day ago

DEADLINE

in about 1 year
View Details
NAICS: 541715
New
Federal
L-PBF Development of ODS Alloys for Recording Methane/Oxygen Combustion Properties
Solicitation # 80NSSC27946801Q
The NASA Shared Services Center is seeking capability statements for a project focused on the laser powder bed fusion (L-PBF) development of oxide dispersion strengthened (ODS) and burn-resistant nickel-based alloys, including GRX-810, GRX-810+, and GRX-900. The scope of work involves advanced process development and parameter optimization using an EOS M280 system to achieve a relative density of 99.9 percent or higher. Key requirements include the production of test coupons and representative components, the supply of at least 600 kg of GRX-810 powder, and strict adherence to NASA-STD-6030 for mechanical validation. All deliverables must be shipped to the Marshall Space Flight Center in Huntsville, Alabama. This procurement is being conducted as a commercial items or services acquisition under FAR Part 12, with NAICS code 541715. NASA intends to issue a sole source contract to North American Manufacturing Pros LLC under FAR 12.102(a); however, the agency is requesting capability statements from other interested organizations to determine if the procurement should be conducted on a competitive basis. Interested parties must submit their qualifications to the primary point of contact, Cara Craft, by October 22, 2026. The contract requires rigorous documentation, including real-time reporting of anomalies and full powder traceability certifications covering chemical composition and particle morphology.
NASA Shared Services Center

POSTED

1 day ago

DEADLINE

in 1 day
View Details
NAICS: 541715
New
Federal
Prototype development for Battlefield Wound Infection Prevention and Treatment (BWI P&T) Barrier Combination
Solicitation # HT9427-26-R-E020
The Defense Health Agency Contracting Activity is seeking a single award for the development of a Battlefield Wound Infection Prevention and Treatment Barrier Combination prototype. This product must integrate a physical wound barrier with antimicrobial and antifungal properties to prevent the spread of organisms and systemic infections in combat scenarios. The project aims to advance technologies from a preferred Technology Readiness Level of 5 or higher to a final state of TRL 7 or 8, culminating in mandatory U.S. Food and Drug Administration approval or clearance. The scope of work includes preclinical testing, human clinical trials, and the submission of regulatory packages such as New Drug Applications or Premarket Approval Applications. This procurement is conducted under prototype Other Transaction Authority 10 U.S.C. 4022, meaning standard FAR and DFARS regulations do not apply unless expressly referenced. The estimated period of performance is 48 months, divided into three primary objectives: prototype demonstration, clinical studies and regulatory submissions, and final FDA clearance. Proposals are due by November 6, 2026, and must be submitted in three distinct volumes covering technical approach, management capability, and administrative cost and price. To be eligible, offerors must be registered in the System for Award Management and meet specific criteria, such as being a nontraditional defense contractor or a small business.
Defense Health Agency

POSTED

1 day ago

DEADLINE

in 17 days
View Details